ReviewJournal of stroke2026
Precision Oxygen Modulation in the Reperfusion Era: Conditioning and Therapeutic Strategies in Ischemic Stroke.
Review in Journal of stroke, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Endovascular thrombectomy (EVT) and advanced perfusion imaging have transformed acute ischemic stroke (AIS) treatment, yet tissue hypoxia may persist because of delayed presentation, incomplete reperfusion, microvascular no-reflow, and secondary injury. Oxygen is an essential substrate for cerebral metabolism and a modifiable therapeutic exposure; however, clinical studies of oxygen-based interventions have yielded inconsistent results because of heterogeneity in timing, dose, delivery, and patient selection. Here we propose precision oxygen modulation (POM) as a stage-, phenotype-, and tissue-informed framework for the reperfusion era-treating oxygen exposure as a dose-titrated therapy that must be matched to the right patient, time window, physiological target, and safety boundary. POM integrates oxygen conditioning strategies that may prime neurovascular resilience before or around ischemia, time-limited therapeutic oxygen strategies deployed around reperfusion to support tissue at risk, and recovery-stage strategies paired with rehabilitation. We synthesize clinical and preclinical evidence linking oxygen tension to excitotoxicity, oxidative stress, inflammation, endothelial dysfunction, blood-brain barrier (BBB) integrity, and repair, while emphasizing the context-dependent risks of hyperoxia. We outline an operational decision framework and translational roadmap based on phenotype- and imaging-guided selection, biomarker validation, protocolized dosing, predefined safety boundaries, and phenotype-enriched randomized trials. POM is presented as a testable translational framework for organizing heterogeneous evidence and guiding the prospective validation of stage-specific oxygen modulation in modern stroke care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.